Kornimate/medical-research-clean huggingface dataset:
investigation of subclinical markers of multiple sclerosis

Conditions: Multiple Sclerosis; Relapsing Remitting Multiple Sclerosis

Summary: transcranial magnetic stimulation (tms) studies reported consistent and substantial impairments in the central nervous system (cns) in multiple sclerosis (ms). studies of peripheral nervous system (pns) function comprising electromyoneurography (emng) reported impairments of the pns in ms that were less pronounced and inconsistent. neurophysiological studies are generally small and cross-sectional and with the poor grouping of ms patients according to ms type. the objective of the study is to investigate clinical, neurophysiological, and immunological markers in relapsing-remitting ms patients, and in patients with relapsing-remitting ms treated with immunomodulation. the results of the study may contribute to a better understanding of the pathophysiology of multiple sclerosis and can provide guidance in the diagnosis and treatment of patients with relapsing-remitting ms.

the following techniques will be applied: * neurophysiological testing will be performed with navigated transcranial magnetic stimulation (ntms) incorporating an individual mri of each subject's brain performed on a 1,5 mri scanner using a series of neuropsychological protocols. mapping of the primary motor cortex for upper and lower extremity muscles with a recording of motor evoked potentials (mep) will be performed. * electromyoneurography (emng) assessment of lower and upper extremities for motor and sensory nerves; * neuropsychological assessment will include the general questionnaire and battery of cognitive and psychological tests; * immunoassays on blood samples include determination of different markers on monocytes and lymphocytes using flow cytometry, as well as determination of cd163 in serum samples using elisa. * clinical examinations include neurological, biochemical, neuroradiological, and neuropsychological testing.

Eligibility criteria:
inclusion criteria: * subjects with a documented diagnosis of relapsing-remitting ms according to the mc donald criteria (2005) and with edss achievement of 0-3.5 according to the modified kurtzke's edss (expanded disability status scale) for the assessment of neurological function and incapacity of patients with multiple sclerosis exclusion criteria: * patients with metals in the body (e.g. pacemaker, dentures) * patients with new pregnancies (verbally confirmed) * patients with new head trauma * subjects unwilling to sign a consent or follow study procedures

Keywords: multiple sclerosis relapsing remitting tms cytometry elisa corticosteroids immunomodulation
proof of concept study of latanoprost/minoxidil (anr-001.1) topical formulation

Conditions: Hypotrichosis

Summary: study to evaluate the safety and efficacy of a latanoprost/minoxidil formulation vs. placebo for the treatment of hypotrichosis of the eyebrows.

a single-blind placebo controlled trial of the efficacy and safety of the treatment of hypotrichosis of the eyebrows comparing a subset of patients receiving a combination of latanoprost/minoxidil formulation as compared to placebo measured by a validated imaging system.

Eligibility criteria:
inclusion criteria: • subjects, age 22 to 65 years, in general good health. * patients with diagnosed hypotrichosis of the eyebrows. * subjects with active hair loss within the last 12 months. * patients willing to refrain from initiation of any new vitamins or nutritional supplements for the duration of the study. * patients willing to refrain from use of any hair growth therapies (oral or topical) other than the investigational product. exclusion criteria: • subjects with an active disease or infection, or chronic dermatological condition (eczema, psoriasis, infection, etc.) of the scalp that may interfere with the assessment of scalp skin health in the treated regions. * history of hair transplants, scalp reduction, current hair weave or tattooing in the target area, artificial hair coloring two months prior to initiation of study which makes it difficult to perform hair count assessment. * subjects with hair loss for greater than 5 years, as medical therapy is unlikely to have much effect at restoring hair follicles inactive for that long of a time period. * subjects with a history of chemotherapy, receiving cytotoxic agents, radiation, or laser/surgical therapy of the scalp within the past 12 months. * any known or underlying medical problem that could influence hair growth such as hiv infection, connective tissue disease, a thyroid condition, inflammatory bowel disease or other medical conditions, at the discretion of the investigator. * subjects with clinical diagnosis of hair loss other than hypotrichosis of the eyebrows. * subjects with severe cardiovascular disease, uncontrolled or untreated hypertension, arrythmia or clinically relevant hypotension. * subjects with known or suspected hypersensitivity or allergic reaction to any of the active or inactive components of the test articles. * pregnant or lactating females or planning to become pregnant for the duration of the study. * subjects using medications that potentially cause drug-induced hair loss (e.g., depotestosterone, haloperidol, methotrexate, methylprednisolone, prednisone, testosterone, divalproex sodium) within the last 3 months. * current enrollment in any other investigational medication (drug) study within the 4 weeks prior to study initiation. * current or recent (2 months) history of severe diet or eating disorder.

Keywords: eyebrow
study of the guardian system on motor recovery and impact on length of stay in ischemic stroke patients

Conditions: Ischemic Stroke

Summary: this is a non-blinded randomized study that will investigate whether the use of a novel, non-invasive perfusion enhancement system (the guardian system) impacts motor recovery and hospital length of stay in acute ischemic stroke patients.

this clinical research study is a prospective, non-blinded randomized clinical trial. the study protocol and consent form have been approved by the irb at the study institution. as per the study design, consecutive adult patients admitted to the neuro-intensive care unit, with acute ischemic stroke, meeting the inclusion and exclusion criteria will be consented and enrolled in the study. both the study and control groups will receive the standard of care for ischemic stroke according to the hospitals' protocols, policies and procedures. after obtaining informed consent, patients in the study arm will have the non-invasive perfusion enhancement system (the guardian system) placed on their beds and chairs. the inflatable surfaces (the enhancers) will be placed directly on the mattress and chair under the fitted sheet and bed linens. they will be secured with a non-porous, non-slip silicone attacher. an adaptive pressure controller will be attached to the perfusion enhancer through a connector set. the adaptive pressure controller will be secured to the bed foot board or side rail and have the ability to be secured to an intravenous pole as necessary. specific data points for each patient in the experimental group will be entered into the controller: they include the patient's weight in kilograms and the patient's position (bed or chair). this study seeks to evaluate the device's effect on motor recovery and length of stay in a homogeneous ischemic stroke population that will be randomized for use of the novel non-invasive perfusion enhancement device from admission to discharge.

Eligibility criteria:
inclusion criteria: * only acute ischemic stroke patients * baseline modified rankin score of less than or equal to 0-2 * remains hemiplegic (left or right) with motor component score on national institute of stroke health scale of 2-4 on arm/leg with or without thrombectomy/tissue plasminogen activator * insured (medicare or private) exclusion criteria: * dementia or alzheimer diagnosis * concurrent hemodialysis * obesity with body mass index greater than 33 * baseline modified rankin score of 3 to 5 * patients requiring ventilator support of greater than 2 days * peripheral neuropathy * concurrent deep vein thrombosis or venous thromboembolism * presence of concurrent pre-existing pressure injury * prolonged inconsistent use of perfusion therapy defined as two or more consecutive hours off of the perfusion enhancement device

Keywords: ischemic stroke motor recovery length of stay reduction
clinical trial of cilostazol eluting stent system (ces-1) in de novo coronary artery lesions

Conditions: Coronary Artery Disease

Summary: the purpose of the this trial is to evaluate the clinical safety and efficacy of cilostazol eluting stent system (ces-1) for the treatment of single de novo lesions in native coronary arteries.


Eligibility criteria:
inclusion criteria: \ 1. patients who have provided written informed consent. 2. patients who have evidence of myocardial ischemia confirmed by subjective symptoms (chest pain etc.), st change in the electrocardiogram or objective findings. 3. patients who are at least 20 years old. \ 1. single de novo lesion in native coronary arteries 2. target vessel diameter is 2.75 mm to 3.25 mm. 3. timi flow is 2 or more. 4. angiographic percent diameter stenosis (by visual estimation) is 75% or more in aha classification exclusion criteria: \ 1. acute myocardial infarction patients whose ck-mb or troponin exceeds the facility reference upper limit and have at least one of the following is confirmed are excluded as acute myocardial infarction. * ischemic symptoms and electrocardiographic findings showing continuous ischemia (eg, st segment elevation or depression above 1 mm in contiguous leads, or the appearance of a new left bundle branch block). * pathological q waves on electrocardiogram * myocardial necrotic focus or wall motion abnormality newly confirmed in diagnostic imaging 2. patients who cannot be given emergency coronary artery bypass grafting (cabg). 3. patients who cannot be administered antiplatelet drugs. the following cases are conceivable. * significant intracranial hemorrhage, gastrointestinal bleeding, urinary tract hemorrhage etc. within the last 6 months * surgical operation is planned that requires discontinuation of dapt after the procedure * anticoagulation therapy is underway and the risk of bleeding is high 4. bleeding tendency due to hemorrhagic diathesis or blood coagulation disorder. 5. left ventricular ejection fraction (lvef) is less than 30% within 30 days before the trial registration. 6. renal dysfunction (creatinine value exceeds 2.0 mg/dl or in case artificial dialysis). 7. allergy to cobalt chrome alloy or contrast agent. 8. patients who are participating in or will planning to participate in other clinical studies that may have clinical implications for the evaluation of this trial. 9. patients who are pregnant or breast feeding. 10. patients who are taking cilostazol. 11. in cases where the investigator determines that the patient's participation in the trial is inappropriate. \ 1. lesion in left main coronary trunk 2. lesion within 5 mm from the ostium right coronary artery 3. lesion within 5 mm from the ostium left anterior descending/the ostium left circumflex branch 4. bifurcation lesion 5. within 1 year after implementing pci on the target vessel or its branch 6. there are other lesions that require pci at the time of the procedure 7. type c of acc / aha classification

Keywords: drug eluting stents coronary artery disease coronary artery stenosis myocardial ischemia angioplasty
effect of sleep apnea treatment on temporo-mandibular disorders

Conditions: Sleep Apnea; Sleep Apnea, Obstructive; Sleep Apnea Syndromes; Pain; Pain, Face; Temporomandibular Disorder

Summary: aims of this research are to detect if an improvement in sleep pattern in patients suffering from obstructive sleep apnea (osa), produces a reduction in pain and dysfunction in the orofacial area by examining variation in temporo-mandibular disorder (tmd) signs and symptoms and if the prevalence of tmds in osa patients controlling this disease decreases to levels comparable to healthy subjects. 41 osa patients will undergo a complete tmd examination prior to start any osa treatment and after at least 18 months of therapy. variations in tmd signs and symptoms will be recorded.

since a bidirectional relationship has been suggested for poor sleep and pain and considering that patients suffering from obstructive sleep apnea (osa) have been reported to present a higher prevalence of temporo-mandibular disorder (tmd) signs and symptoms compared to healthy controls; aims of this research are to detect if an improvement in sleep pattern in patients suffering from osa, produces a reduction in pain and dysfunction in the orofacial area by examining variation in tmd signs and symptoms and if the prevalence of tmds in osa patients controlling this disease decreases to levels comparable to healthy subjects. 41 osa patients will undergo a complete tmd examination prior to start any osa treatment and after at least 18 months of therapy. variations in tmd signs and symptoms will be recorded.

Eligibility criteria:
inclusion criteria: * patients suffering from osa diagnosed by polysomnography not yet undergoing treatment exclusion criteria: * patients presenting some kind of cognitive impairment, due to difficulties in undergoing tmd examination * patients presenting dental problems * patients assuming medications that would alter pain perception * patients not signing the informed consent

Keywords: pain sleep apnea temporo-mandibular disorders
postoperative hyperthyroidism

Conditions: Hyperthyroidism

Summary: the purpose of this study is to evaluate the frequency and the clinical course of postoperative hyperthyroidism following surgery of tertiary hyperparathyroidism (thp) and to determine the diagnostic value of thyroglobulin in this setting.


Eligibility criteria:
inclusion criteria: * patients with tertiary hyperparathyroidism undergoing surgery for this reason * dialysis treatment exclusion criteria: * patients wish

Keywords: hyperthyroidism tertiary hyperparathyroidism palpation thyroiditis parathyroidectomy thyroglobulin rate of postoperative hyperthyroidism
using gum arabic for cancer patients to protect from oral mucositis caused by chemotherapy: ِِِan experimental study

Conditions: Chemotherapy-induced Oral Mucositis

Summary: this study was designed to investigate the effect of gum arabic (ga) on cancer patients to prevent chemotherapy-induced oral mucositis. cancer patients who will receive chemotherapy were divided into two groups; study "gum arabic" group (which received ga with chemotherapy) and control group (chemotherapy alone); and the participants were recruited to reach 190 patients in the study group and 184 patients in control group. this clinical trial was conducted in outpatient chemotherapy sections at radiation and isotopes center of khartoum. this study was designed to test the theory that say the chemotherapy-induced oral mucositis will significantly decrease after ingestion 30 grams as daily dose of gum arabic in a form of solution for six weeks during therapy.


Eligibility criteria:
inclusion criteria: * patients whom well diagnosed with cancer in any stage were eligible for enrolment if chemotherapy is part of their treatment plan. exclusion criteria: patients were excluded if * they had received recent previous chemotherapy or radiotherapy, * they had oral mucositis or periodontitis, * there is evidence of any systemic diseases.

Keywords: gum arabic cancer patients chemotherapy oral mucositis
extern validation of a predictive score of brain death in severe stroke (diapason1)

Conditions: Stroke

Summary: there is currently a shortage of organ in france, for patients with chronic diseases who are on the waiting list for an organ. the first source of organ donor in france is patients with brain death. 58% of patients in brain death are patients with a severe stroke ( ischemic or hemorrhagic). in order to identify which patient with a severe stroke and with unfavorable prognosis who can evolve to brain death, we have conducted a retrospective study in lorrain, in france, and we have built a predictive score of brain death in these patients. it is important to validate this predictive score in a prospective study on a greater scale than the first study.

main objective : external validation of a brain death evolution predictive score grahal65 (initial glasgow score ≤6, systolic blood pressure \>150 mmhg, past history of alcohol abuse, herniation, hydrocephalus, and stroke volume\>65 ml) for patients with severe stroke and withhold therapy built. secondary objectives : identification of other clinical and paraclinical predictive factors of brain death evolution: * age,sex, * temperature and glycemia * rostro-caudal abolition of brainstem reflexes * other cardiovascular risk factors (hypertension, diabetes, atrial fibrillation, dyslipidemia,) * antiplatelet therapy, anticoagulant treatment, * intravenous thrombolytic therapy or thrombectomy * type of stroke * infarct location * type of brain herniation

Eligibility criteria:
inclusion criteria: * patient aged 18 years and over. * patient with a sever stroke less than 48 hours diagnosed by brain imaging magnetic resonance imaging or computed tomography (including cerebral infarction, intra-parenchymal hemorrhage and subarachnoid haemorrhage * patient with glasgow scale score \<8 engaged vital prognosis * absence of therapeutic resources * decision of resuscitation measures to protect the organs in the purpose organ donation after brain death exclusion criteria: * pregnant woman * patient with recent traumatic brain injuries (subdural hematoma, extradural hematoma and contusions) * obvious contraindication of organ donation excluding the patient from organ protection measures in intensive care unit (expression of patient opposition, hiv infection, active tuberculosis, spongiform encephalopathy, * human growth hormones treatment origin, rabies, active cancer) * opposition of family member of the patient

Keywords: severe stroke brain death organ donation
uroflowmetry results and vitamin d levels

Conditions: Lower Urinary Tract Symptoms; Vitamin D Deficiency; Calcium Deficiency

Summary: the investigators aimed to evaluate the relationship between luts and vitamin d with uroflowmetry parameters in female patients. they found no relation between vitamin d levels and luts in respect to uroflowmetry. however, in low vitamin d patients, ca is related with urologic problems. the investigators believe that there is a need for studies emphasizing serum ca levels in addition to vitamin d levels in patients with luts.

this retrospective cohort study included 186 female patients who admitted to luts. demographic characteristics, medical history, calcium (ca) and vitamin d including laboratory studies and uroflowmetry results as maximum urine flow rate (qmax), average urine flow rate (qav), and voided volume (v) were recorded. patients were divided into two groups according to age (18-50 and ≥51) and vitamin d levels (\<20 and ≥20). laboratory parameters, uroflowmetry results, were compared between groups. the study was approved by the local ethics committee (approval#22/06/2018-09.29-54132726-000-14136). the study was conducted in accordance to the helsinki declaration and good clinical practices guidelines.

Eligibility criteria:
inclusion criteria: clinical diagnosis of low urinary tract symptom exclusion criteria: urinary tract infection, diabetes mellitus, neurological disorder, pregnancy stone disease other urinary system disorders.

Keywords: lower urinary tract symptoms vitamin d deficiency calcium deficiency
a comparison of thermawedge™ device and achilles tendon stretching for the treatment of plantar fasciopathy

Conditions: Plantar Fasciitis; Plantar Fasciopathy

Summary: the investigators will compare achilles tendon stretching with a new product called a thermawedge™ device, a foam wedge designed to help with certain foot stretches and exercises, in the treatment of chronic plantar fasciopathy. there will be 2 groups each of 25 - 30 participants who have chronic plantar fasciopathy, which is a common cause of foot pain. exercises will be done for 6 weeks and then each group will do the other exercise protocol for another 6 weeks. participants will fill out the foot and ankle disability index scale and numerical analog pain scale and the global rating of change scale prior to any treatment, weekly during treatment and post treatment. the investigators' hypothesis is that use of the thermawedge™ device will result in decreased pain and disability when compared to achilles tendon stretching.


Eligibility criteria:
inclusion criteria: * diagnosis of plantar fasciopathy which has persisted (chronic) for at least 12 months. * participants need to be able to understand simple instructions about the stretches which will likely include both verbal instructions and pictures and participants need to be able to do all the necessary exercises. * participants must have current british columbia (bc) medical service plan (msp) health coverage so that if they become injured, they are covered medically. * participants must be able to fill out surveys online. * participants must also pass a clinical screen where a senior medical student or a physiotherapist, scott fraser, will assess the patient for for plantar fasciopathy/fasciitis. exclusion criteria: * previous ankle or foot trauma or surgery * duration of pain of less than 12 months, * those receiving adjuvant treatment such as injections during the time of the study, * those who are unable to do the necessary exercises required in the study * those who do not have current bc msp health insurance coverage.

Keywords: thermawedge tm stretches